CONSULTING AGREEMENTConsulting Agreement • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) dated as of [•], 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [•] (“Consultant”).
AGREEMENT AND PLAN OF MERGER by and among RENEO PHARMACEUTICALS, INC. RADIATE MERGER SUB I, INC. RADIATE MERGER SUB II, LLC and ONKURE, INC. Dated as of May 10, 2024Agreement and Plan of Merger • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of May 10, 2024, by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Parent (“Merger Sub I”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Parent (“Merger Sub II”, and together with Merger Sub I, “Merger Subs”) and OnKure, Inc., a Delaware corporation (the “Company”). Parent, the Merger Subs and the Company are referred to herein collectively as the “Parties” and individually as a “Party.”
LOCK-UP AGREEMENTLock-Up Agreement • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of May 10, 2024 (as the same may be amended from time to time, the “Merger Agreement”) with Radiate Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub I”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Merger Sub II”) and OnKure, Inc., a Delaware corporation (the “Company”). All capitalized terms used in this Lock-Up Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement.
SUBSCRIPTION AGREEMENTRegistration Rights Agreement • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of May 10, 2024 (the “Effective Date”), by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the individuals and entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”).
ONKURE, INC. COMPANY SUPPORT AGREEMENTCompany Support Agreement • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS COMPANY SUPPORT AGREEMENT (this “Agreement”), dated as of [•], 2024 is made by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), OnKure, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Stockholder”) of shares of capital stock (the “Shares”) of the Company.
RENEO PHARMACEUTICALS, INC. PARENT SUPPORT AGREEMENTParent Support Agreement • May 13th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS PARENT SUPPORT AGREEMENT (this “Agreement”), dated as of [•], 2024 is made by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), OnKure, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Stockholder”) of shares of capital stock (the “Shares”) of Parent.
